Effect of Shenmai injection combined with antiplatelet drugs on the plaque property and inflammatory response in patients with non-STsegment elevation ACS

• Main Authors: Xin Lu, Bo Yang
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2018-01-01
• Series: Journal of Hainan Medical University
• Subjects: Non-ST-segment elevation ACS; Shenmai injection; Plaque property; Inflammatory response
• Online Access: http://www.hnykdxxb.com/PDF/201801/03.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To investigate the effect of Shenmai injection combined with antiplatelet drugs on the plaque property and inflammatory response in patients with non-ST-segment elevation ACS. Methods: A total of 142 patients with non-ST-segment elevation ACS who were treated in the hospital between June 2015 and September 2017 were divided into control group (n=71) and Shenmai injection group (n=71) by random number table method. Control group received antiplatelet drugs based on routine treatment, and Shenmai injection group received Shenmai injection combined with antiplatelet drugs on the basis of routine treatment. The differences in serum contents of plaque property-related indexes and inflammatory factors were compared between the two groups before and after treatment. Results: Before treatment, there was no significant difference in serum contents of metabolism indexes, lipid indexes, cell adhesion molecules and inflammatory factors between the two groups. After 1 week of treatment, serum metabolism indexes Hcy and UA contents of Shenmai injection group were lower than those of control group; serum lipid indexes ox-LDL and Lp-PLA2 contents were lower than those of control group; serum adhesion molecules sVCAM-1 and sICAM-1 contents were lower than those of control group; serum inflammatory factors IL-1β, IL-6, IL-17 and IL-23 contents were lower than those of control group. Conclusion: Adjuvant Shenmai injection therapy can further stabilize the plaques and inhibit the systemic inflammatory response in patients with non-ST-segment elevation ACS.